These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169 [TBL] [Abstract][Full Text] [Related]
7. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931 [TBL] [Abstract][Full Text] [Related]
8. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Adi H; Young PM; Chan HK; Agus H; Traini D Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286 [TBL] [Abstract][Full Text] [Related]
10. Erythritol-based dry powder of glucagon for pulmonary administration. Endo K; Amikawa S; Matsumoto A; Sahashi N; Onoue S Int J Pharm; 2005 Feb; 290(1-2):63-71. PubMed ID: 15664131 [TBL] [Abstract][Full Text] [Related]
11. Applicability of DPI formulations for novel neurokinin receptor antagonist. Kumon M; Yabe Y; Kasuya Y; Suzuki M; Kusai A; Yonemochi E; Terada K Int J Pharm; 2008 May; 356(1-2):102-9. PubMed ID: 18294787 [TBL] [Abstract][Full Text] [Related]
12. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability. Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612 [TBL] [Abstract][Full Text] [Related]
13. Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations. Hatanaka J; Kimura Y; Lai-Fu Z; Onoue S; Yamada S Int J Pharm; 2008 Nov; 363(1-2):112-7. PubMed ID: 18706989 [TBL] [Abstract][Full Text] [Related]
14. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. Gervelas C; Serandour AL; Geiger S; Grillon G; Fritsch P; Taulelle C; Le Gall B; Benech H; Deverre JR; Fattal E; Tsapis N J Control Release; 2007 Mar; 118(1):78-86. PubMed ID: 17241685 [TBL] [Abstract][Full Text] [Related]
15. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428 [TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Zheng H; Liu Y; Huang T; Fang Z; Li G; He S Toxicol Lett; 2009 Sep; 189(3):225-34. PubMed ID: 19524650 [TBL] [Abstract][Full Text] [Related]
17. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats. Onoue S; Sato H; Ogawa K; Kojo Y; Aoki Y; Kawabata Y; Wada K; Mizumoto T; Yamada S Eur J Pharm Biopharm; 2012 Jan; 80(1):54-60. PubMed ID: 22008148 [TBL] [Abstract][Full Text] [Related]
18. Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. Seto Y; Suzuki G; Leung SS; Chan HK; Onoue S Pharm Res; 2016 Jun; 33(6):1447-55. PubMed ID: 26975360 [TBL] [Abstract][Full Text] [Related]